

NEWS RELEASE

Sequella Receives U.S. Patent for Transdermal Patch Diagnostic

ROCKVILLE, Md, January 12, 2006-- Sequella, Inc., a privately held biotechnology company developing products for infectious disease, announces the issuance of U.S. Patent No. 6,979,450 covering methods and compositions of its late-stage proprietary diagnostic, a transdermal patch for the detection and diagnosis of active tuberculosis (TB) disease.

The patent provides coverage for the detection and diagnosis of infectious diseases, in particular for the detection of active TB disease, and includes the methods comprising topical application of antigen compositions for transdermal delivery.

“The ‘450 patent builds on the worldwide patent protection strategy for our lead diagnostic product and complements foreign patents issued previously in key infectious disease markets such as China,” said Dr. Carol Nancy, CEO of Sequella. “The patent underpins our corporate goals for managing the product life cycle strategy for this most important R&D asset. It highlights our commitment to serving TB patients worldwide and to commercializing TB diagnostics that may establish a gold standard for point-of-care convenience and greater accuracy in TB diagnosis.”

About Tuberculosis (TB)

TB is a contagious infectious disease caused by the bacterium *Mycobacterium tuberculosis*. TB germs can be inhaled into lungs and are able to avoid destruction by certain white blood cells. Without containment by immune cells, the bacteria can spread throughout the body, multiply, survive and remain dormant for years. TB is the leading cause of global deaths that result from a single-agent infectious disease. The World Health Organization estimates that one-third of the world’s population is currently infected with TB. In 2003 there were a reported 8 million new TB infections worldwide and 2 million deaths from TB.

About Sequella, Inc.

Sequella is a clinical stage biotechnology company that develops and commercializes novel infectious disease products. Sequella conducts discovery and pre-clinical research at its Rockville, Md headquarters, which houses chemistry and microbiology laboratories. Sequella advances new and more effective products for high hazard microorganisms in its BioSafety Level-3 (BSL-3) facility. Our lead product candidate, the Transdermal Patch for diagnosis of TB disease, is completing an international phase III clinical trial in Peru and we expect to file for worldwide registration by 2007. For more information, please visit www.sequella.com

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts and generally can be identified by the use of phrases such as “believe,” “expect,” “plan,” “estimate,” “potential,” “opportunity,” “project,” and similar terms. Actual results could differ significantly from results discussed, including whether products can be successfully developed and commercialized; whether Sequella will enter into future alliances with corporate partners; and other uncertainties. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.

MEDIA CONTACT:

Corporate Development
Sequella, Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850
301-762-7776 (phone); 301-762-7778 (fax)